18 March 1998
Roots of Gavi
Washington, D.C., United States: with immunisation rates in low-income countries in decline and slow progress introducing new vaccines, World Bank President James Wolfensohn convenes a Vaccine Summit involving WHO, UNICEF, vaccine industry leaders, bilateral aid agencies & independent academics.
15 March 1999
Vaccine Development and Delivery
Bellagio, Italy: 2nd Vaccine Summit at Rockefeller Foundation's Study Centre lays foundations for new global coalition to revitalise immunisation rates in poor countries and support purchase of new vaccines like hepatitis B, yellow fever and Haemophilus influenzae type b (Hib).
12 July 1999
Proto-Board of Gavi
Seattle, United States: proto-Board establishes mission, objectives, functions and governance structure for the Global Alliance for Vaccines and Immunisation (GAVI). UNICEF offers to house Gavi's Secretariat in Geneva.
28 October 1999
First GAVI Alliance Board meeting
New York, United States: Dr.Gro Harlem Brundtland, Gavi's first Board Chair, sets challenges:
1. improve vaccine infrastructure in low-income countries;
2. help poorer countries procure vaccines against hepatitis B (hepB), Haemophilus influenzae type B (Hib), yellow fever & safe injection equipment;
3. secure research and development for disease prevalent in poor countries.
23 November 1999
Gates Foundation contribute $750 million
Seattle, United States: The Bill & Melinda Gates Foundation pledge a gift of US$ 750 million over five years to establish the Global Fund for Children's Vaccines, the institution set-up to finance the Vaccine Alliance.
31 January 2000
Gavi launched at WEF, Davos
Davos, Switzerland: Gavi publically launched. A global alliance of public/private stakeholders in immunisation, uniting WHO's technical expertise, UNICEF's vaccine purchasing power, financial know-how of the World Bank, the R&D market knowledge of vaccine industry & the voices of developing countries.
11 February 2003
Accelerated Development and Introduction Plans
Baltimore, United States: Gavi awards two US$ 30 million grants to the Johns Hopkins Bloomberg School of Public Health in Baltimore and PATH in Seattle to make the case for introducing new vaccines against rotavirus and pneumococcal diseases quickly in developing countries.
15 July 2003
Over US$1 billion committed
Washington, D.C.: Gavi's five-year commitments to immunise children in the world's poorest countries top US$ 1 billion. Some 68 countries now receive support for health infrastructure, vaccines and supplies through Gavi funding.
11 October 2004
World Vaccine Congress
Lyon, France: Gavi reveals that its support has helped new vaccines reach nearly 45 million children since 2000, saving 500,000 lives. Many countries have only been able to access vaccines against hepatitis B (hepB) and Haemophilus influenzae type b (Hib) because of Gavi funding.
Health system strengthening support
Paris, France: Gavi starts to offer health system strengthening support (HSS) parallel with vaccine support. This will help countries create more integrated health plans that remove bottlenecks in the delivery of immunisation and other health services. For example, funding health worker training.
7 December 2005
Hib Initiative launched at 3rd Partners' Meeting
New Delhi, India: Gavi designates US$ 37 million to fund the Hib Initiative -- a consortium of experts from the Johns Hopkins Bloomberg School of Public Health, the London School of Hygiene & Tropical Medicine, the Centers for Disease Control and Prevention & WHO, who will help developing countries adopt the Haemophilus influenzae type b (Hib) vaccine against childhood pneumonia and meningitis.
14 November 2006
IFFIm issues inaugural Vaccine Bonds
London, UK: Gavi's International Finance Facility for Immunisation (IFFIm) raises US$ 1 billion through the inaugural issue of bonds to institutional investors. IFFIm converts long-term government pledges of aid into immediately available cash by issuing bonds in the capital markets.
29 November 2006
Gavi to finance rotavirus vaccines
Berlin, Germany: GAVI Alliance Board approves proposal to help low-income countries purchase rotavirus vaccines as quickly as possible after their introduction in the United States and the European Union. Almost 90% of childhood deaths from rotavirus diseases occur in the developing world.
9 February 2007
Advance Market Commitment launched
Rome, Italy: Advance Market Commitment (AMC) launched to create a market in the world's poorest countries for a new vaccine against pneumococcal disease. Canada, Italy, Norway, the Russian Federation, the UK and the Bill & Melinda Gates Foundation commit US$ 1.5 billion.
5 September 2007
International Health Partnership
London, UK: Gavi signs-up to the International Health Partnership (IHP) mission to strengthen health systems in developing countries by addressing health worker staffing, infrastructure, health commodities, logistics, tracking progress and effective financing.
28 November 2007
IFFIm: almost US$ 1 billion in first year
Cape Town, South Africa: thanks to the International Finance Facility for Immunisation's (IFFIm) first bond sale in 2006, Gavi has provided US$ 995 million to 43 of the world's poorest countries to spend on life-saving immunisation and health programmes.
4 March 2008
Japanese investors welcome Vaccine Bonds
Tokyo, Japan: Second International Finance Facility for Immunisation (IFFIm) bond sale secures US$ 223 million from private investors in Japan. As guaranteed source of predictable funding, IFFIm gives poor countries confidence to make long-term investments in vaccine programmes.
23 May 2008
Gavi invests in strengthening health systems
Geneva, Switzerland: to meet rising demand from developing countries, Gavi increases funding for health system strengthening (HSS) to US$ 800 million. Weak health systems are one of the main obstacles to scaling up immunisation and other life-saving interventions.
25 June 2008
New vaccine strategy
Geneva, Switzerland: GAVI Alliance Board agrees to consider future support of new and underused vaccines against four deadly diseases in the developing world: human papillomavirus (HPV), typhoid, Japanese encephalitis and rubella.
3 March 2009
New Vaccine Investment ISA
London, UK: Vaccine investment ISA goes on sale in the UK, aiming to raise GBP 50 million for the International Finance Facility for Immunisation (IFFIm). Every GBP 1,000 invested will help Gavi fund the immunisation of over 130 children against five life-threatening diseases.
12 June 2009
Advance Market Commitment pilot activated
Lecce, Italy: Italy, the UK, Canada, Russia, Norway and the Bill & Melinda Gates Foundation, together with Gavi partners World Bank, UNICEF and WHO, formally activate the Advance Market Commitment (AMC) pilot project against pneumococcal disease by signing legal agreements.
23 June 2009
Gavi recognised as international institution
Geneva, Switzerland: Gavi, hosted by UNICEF since its launch in 2000, becomes an independent international institution - the first organisation to receive such recognition under the Swiss Host State Act.
New funding to strengthen health systems
New York, United States: United Kingdom, Australia and Norway affirm success of the International Finance Facility for Immunisation (IFFIm) with announcement of US$1 billion commitment to expanding IFFIm support for Gavi.
30 April 2010
Guyana introduces rotavirus vaccine
Georgetown, Guyana: Guyana becomes the fourth Gavi-eligible country to introduce a vaccine against rotavirus, the primary cause of diarrhoea which is the second biggest killer of under-fives in developing countries. Bolivia, Honduras and Nicaragua have already introduced rotavirus vaccine with Gavi support.
18 August 2010
Health Systems Funding Platform in Nepal
Kathmandu, Nepal: Nepal takes a first step toward implementing the Health Systems Funding Platform as its leading aid donors - DFID, World Bank, Gavi, USAID, UNFP and UNICEF - sign a Joint Financing Arrangement to funnel their financial support for the national health system through a single aid management system.
6 October 2010
Call for Action and Resources
New York, United States:at a high-level meeting entitled "Saving children's lives - a call for action and resources for the Vaccine Alliance", Gavi donors and partners agree to convene the Alliance's first pledging conference in June 2011. Its objective: ensuring that the Alliance has sufficient funding to introduce new vaccines against the two biggest killers of children - pneumonia and diarrhoea - between 2010 and 2015.
30 November 2010
Dagfinn Høybråten elected new GAVI Alliance Board Chair
Kigali, Rwanda: former Norwegian Minister of Health and current member of parliament Dagfinn Høybråten is unanimously elected by the GAVI Alliance Board as its new Chair. Mr. Høybråten will take over responsibility from Mary Robinson, the international human rights advocate.
12 December 2010
Nicaragua introduces pneumococcal vaccine
Managua, Nicaragua: A new vaccine which prevents the most deadly forms of pneumonia - the world's number one killer of children - is introduced in the routine immunisation programme of a developing country, paving the way to introductions in more than 40 developing countries.
14 February 2011
Global roll out of pneumococcal vaccine
Nairobi, Kenya: hundreds of children in Kenya receive their first shots against pneumococcal disease at a special event to mark the global roll-out of vaccines targeting the world's biggest chid killer, pneumonia. With Gavi support, Nicaragua, Guyana, Yemen and Sierra Leone have also introduced the vaccine.
8 March 2011
New CEO Seth Berkley
Geneva, Switzerland: Gavi appoints Dr. Seth Berkley as its new Chief Executive Officer. The President, CEO and founder of the International AIDS Vaccine Initiative (IAVI), Dr. Berkley is a Harvard-trained physician, CDC-trained epidemiologist and a leading global vaccines advocate.
11 May 2011
Geneva, Switzerland: Gavi commits US$ 100 million to supporting the roll-out of a new life-saving vaccine MenAfriVac in Cameroon, Chad and Nigeria. Developed at around US 50 cents per dose, the MenAfriVac vaccine specifically addresses group A meningococcal meningitis and will save tens of thousands of lives in Africa's "meningitis belt".
10 June 2011
Record demand for Gavi vaccines
Geneva, Switzerland: record 50 Gavi-eligible countries apply for Gavi's vaccine funding, nearly double the previous high of 27. Of 75 applications, the majority are for pneumococcal and rotavirus vaccines, that protect against the biggest global killers of children -- pneumonia and diarrhoea respectively.
13 June 2011
Historic milestone in global health
London, UK: major public and private donors commit US$ 4.3 billion at the first pledging conference held by Gavi. The figures exceends an initial target of US$ 3.7 billion and ensures Gavi can immunise more than a quarter of a billion children in developing countries by 2015.